Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
IPSEN stock logo
IPSEY
IPSEN
$46.50
$47.34
$29.05
$51.10
$15.59B0.42578 shs42 shs
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$5.88
+8.3%
$4.43
$3.53
$8.59
$512.85M1.731.70 million shs5.20 million shs
Neogen Corporation stock logo
NEOG
Neogen
$9.58
+0.7%
$9.09
$4.56
$11.43
$2.07B1.82.03 million shs5.34 million shs
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$16.68
+4.1%
$13.94
$7.95
$28.25
$2.24B1.926.39 million shs9.81 million shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
IPSEN stock logo
IPSEY
IPSEN
0.00%+6.04%-0.21%+7.91%+60.07%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
+8.29%+29.40%+49.62%+37.38%+14.84%
Neogen Corporation stock logo
NEOG
Neogen
+0.74%+2.90%+4.13%+10.11%+96.71%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
+4.05%+6.45%+24.11%+34.84%+74.48%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
IPSEN stock logo
IPSEY
IPSEN
$46.50
$47.34
$29.05
$51.10
$15.59B0.42578 shs42 shs
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$5.88
+8.3%
$4.43
$3.53
$8.59
$512.85M1.731.70 million shs5.20 million shs
Neogen Corporation stock logo
NEOG
Neogen
$9.58
+0.7%
$9.09
$4.56
$11.43
$2.07B1.82.03 million shs5.34 million shs
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$16.68
+4.1%
$13.94
$7.95
$28.25
$2.24B1.926.39 million shs9.81 million shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
IPSEN stock logo
IPSEY
IPSEN
0.00%+6.04%-0.21%+7.91%+60.07%
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
+8.29%+29.40%+49.62%+37.38%+14.84%
Neogen Corporation stock logo
NEOG
Neogen
+0.74%+2.90%+4.13%+10.11%+96.71%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
+4.05%+6.45%+24.11%+34.84%+74.48%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
IPSEN stock logo
IPSEY
IPSEN
2.20
HoldN/AN/A
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
2.00
Hold$6.5010.54% Upside
Neogen Corporation stock logo
NEOG
Neogen
2.17
Hold$10.6711.34% Upside
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
2.35
Hold$20.4622.64% Upside

Current Analyst Ratings Breakdown

Latest NTLA, NEOG, MYGN, and IPSEY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
DowngradeSell (D-)Sell (E+)
6/16/2026
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Reiterated RatingBuy$49.00
6/15/2026
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Set Price Target$25.00
6/15/2026
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Reiterated RatingBuy$25.00
6/15/2026
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Reiterated RatingMarket Outperform
6/15/2026
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Reiterated RatingNeutral$12.00
6/15/2026
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
Reiterated RatingMarket Outperform$30.00
6/5/2026
IPSEN stock logo
IPSEY
IPSEN
Initiated CoverageBuy
6/4/2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
UpgradeSell (E+)Sell (D-)
5/29/2026
IPSEN stock logo
IPSEY
IPSEN
UpgradeHold
5/18/2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
DowngradeSell (D-)Sell (E+)
(Data available from 6/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
IPSEN stock logo
IPSEY
IPSEN
$4.16B3.75$5.51 per share8.44$14.64 per share3.18
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
$824.50M0.67$4.08 per share1.44$3.95 per share1.49
Neogen Corporation stock logo
NEOG
Neogen
$870.56M2.40$5.81 per share1.65$9.54 per share1.00
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
$67.67M34.44N/AN/A$5.80 per share2.88
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
IPSEN stock logo
IPSEY
IPSEN
$501.78MN/AN/A12.11N/AN/AN/AN/A7/30/2026 (Estimated)
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
-$365.90M-$4.30N/AN/AN/A-48.24%-8.51%-4.48%8/4/2026 (Estimated)
Neogen Corporation stock logo
NEOG
Neogen
-$1.09B-$2.80N/A43.554.26-69.93%2.35%1.46%8/4/2026 (Estimated)
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
-$412.69M-$3.54N/AN/AN/A-597.04%-57.47%-46.24%8/6/2026 (Estimated)

Latest NTLA, NEOG, MYGN, and IPSEY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/11/2026Q1 2026
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
-$0.92-$0.81+$0.11-$0.81$13.81 million$15.05 million
5/5/2026Q1 2026
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
-$0.06-$0.09-$0.03-$0.36$202.42 million$200.40 million
4/9/2026Q3 2026
Neogen Corporation stock logo
NEOG
Neogen
$0.04$0.09+$0.05-$0.08$204.62 million$211.20 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
IPSEN stock logo
IPSEY
IPSEN
$0.300.65%N/AN/AN/A
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
N/AN/AN/AN/AN/A
Neogen Corporation stock logo
NEOG
Neogen
N/AN/AN/AN/AN/A
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
IPSEN stock logo
IPSEY
IPSEN
N/A
1.96
1.79
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
0.36
2.40
2.19
Neogen Corporation stock logo
NEOG
Neogen
0.38
3.92
2.84
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
N/A
6.10
6.10

Institutional Ownership

CompanyInstitutional Ownership
IPSEN stock logo
IPSEY
IPSEN
N/A
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
99.02%
Neogen Corporation stock logo
NEOG
Neogen
96.73%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
88.77%

Insider Ownership

CompanyInsider Ownership
IPSEN stock logo
IPSEY
IPSEN
N/A
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
1.90%
Neogen Corporation stock logo
NEOG
Neogen
0.55%
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
3.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
IPSEN stock logo
IPSEY
IPSEN
5,358335.26 millionN/ANot Optionable
Myriad Genetics, Inc. stock logo
MYGN
Myriad Genetics
2,70094.45 million92.65 millionOptionable
Neogen Corporation stock logo
NEOG
Neogen
2,110217.67 million216.48 millionOptionable
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
600139.72 million134.83 millionOptionable

Recent News About These Companies

Positive Phase III results for Intellia’s lonvo-z
5 Most Shorted Mid-Cap and Small-Cap Stocks to Buy Now

New MarketBeat Followers Over Time

Media Sentiment Over Time

IPSEN stock logo

IPSEN OTCMKTS:IPSEY

$46.50 0.00 (0.00%)
As of 06/26/2026

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

Myriad Genetics stock logo

Myriad Genetics NASDAQ:MYGN

$5.88 +0.45 (+8.29%)
Closing price 06/26/2026 04:00 PM Eastern
Extended Trading
$5.69 -0.19 (-3.16%)
As of 06/26/2026 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Neogen stock logo

Neogen NASDAQ:NEOG

$9.58 +0.07 (+0.74%)
Closing price 06/26/2026 04:00 PM Eastern
Extended Trading
$9.59 +0.01 (+0.10%)
As of 06/26/2026 07:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods. The segment offers its products primarily to milling and grain, meat and poultry, prepared foods and ingredients, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products, and genomics testing services marketed through veterinarians, retailers, livestock producers, and animal health product distributors, for the animal safety market. The segment offers its products for companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. Neogen Corporation was incorporated in 1981 and is headquartered in Lansing, Michigan.

Intellia Therapeutics stock logo

Intellia Therapeutics NASDAQ:NTLA

$16.68 +0.65 (+4.05%)
Closing price 06/26/2026 04:00 PM Eastern
Extended Trading
$16.63 -0.05 (-0.32%)
As of 06/26/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.